Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

New research into GLP-1 receptor has opened a realm of new treatment possibilities to treat opioid use disorder (OUD), a ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Medical treatments, including jabs used for weight loss, are monitored in part using the Medicines and Healthcare products ...

Drugs approved for diabetes and obesity might be useful for the treatment of cognitive and mental health disorders, according ...

A target trial emulation study compared risk for depression among older adults with type 2 diabetes initiating treatment with ...

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent study.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Data submitted to the UK drugs regulator show a total of 82 deaths related to glucagon-like peptide-1 receptor agonists, the class of drugs used for weight loss and type 2 diabetes. Data from the ...

The NHS medical director has cautioned about the side effects of certain medications following the latest findings ...

Recent research found that weight loss drugs like Ozempic may be contributing to a national trend of thyroid cancer ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...